Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1

Interventions

pembrolizumab 44Carboplatin 40Cisplatin 36Paclitaxel 29Pemetrexed 24Nivolumab 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Fluorouracil 14Capecitabine 14atezolizumab 13Docetaxel 13trastuzumab deruxtecan 12Trastuzumab 12Lenalidomide 12durvalumab 11daratumumab 11Cytarabine 11olaparib 10Prednisone 10Bortezomib 10Bevacizumab 10130-nm albumin-bound paclitaxel 10Doxorubicin 9venetoclax 8Oxaliplatin 8Crizotinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has announcements × idelalisib × Clear all
NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Acerta Pharma BV

Phase 3 Active not recruiting
310 enrolled 18 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡